A Phase 1 interventional study of AT-527 and AT-527 in Healthy Volunteer and Renal Impairment, sponsored by Atea Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Renal Insufficiency with a site in Canada — 7 open to participants now, 9 under way, none of them phase 3. Renal Insufficiency · Canada.
Among the 79 studies in Renal Insufficiency with a site in Canada, this one is the 44th largest by enrollment of the 65 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 1, and was the 74th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →7 of the 79 studies in Renal Insufficiency with a site in Canada are open now. Recruiting first, the newest first:
Seven Oaks Hospital Chronic Disease Innovation Centre · Sites in Canada
Ages 18+
The University of Queensland · Sites in Canada, Australia
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Medtronic · Sites in Canada, United States, Argentina and 38 more countries
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 13 · Phase 4 8
First in 1996; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 75 across the 65 interventional studies, 457 across the 14 observational. Of the 61 that completed or were terminated, 16 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 79 have an industry lead sponsor. The 10 most frequent:
Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.
Atea Pharmaceuticals, Inc. has 2 studies filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05242315University of AlbertaExtended-Release Tacrolimus Following Liver Transplantation | 2026-12-15 |
| NCT04561362BicycleTx LimitedStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | 2027-01 |
| NCT06396702University Health Network, TorontoEASE-SOT Pilot Study | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 79 studies in Renal Insufficiency with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study of AT-527 in Subjects with Normal and Impaired Renal Function
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with Normal Renal Function (Group E):
Renal Impaired Subjects (Groups A, B, and C):
Subjects with End-Stage Renal Disease -ESRD (Group D)
Exclusion Criteria:
Subjects with Normal Renal Function (Group E):
Subjects with Impaired Renal Function (Group A, B, C and D):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose AT-527
Drug: AT-527
single dose AT-527
Drug: AT-527
single dose AT-527
Drug: AT-527
single dose of AT-527 pre- and post-dialysis
Drug: AT-527
Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
Drug: AT-527 and Probenecid
single dose AT-527
Also known as: Bemnifosbuvir
Single dose of AT-527 pre- and post-dialysis
Also known as: Bemnifosbuvir
Drug pages: Bemnifosbuvir · Probenecid
Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
Also known as: Bemnifosbuvir
Pharmacokinetics (PK) of AT-527 Maximum plasma concentration (Cmax)
Time frame: Day 1
Pharmacokinetics (PK) of AT-527 Area under the plasma concentration-time curve (AUC)
Time frame: Day 1
Pharmacokinetics (PK) of AT-527 AUC
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Jun 2024, 19 months.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 19 months is above that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bemnifosbuvir · Probenecid